Knott David M Jr reported 71 positions worth $173.52M for the quarter ended Jun 30, 2026, up 19.1% on the prior quarter. It opened 8 new positions, added to 15, trimmed 4 and exited 6. Its largest holding is Alphabet Inc. at 18.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CLST Catalyst Bancorp, Inc. | +114.0K | – | $3.58M | 2.06% |
| SPRB Spruce Biosciences, Inc. | +20.0K | – | $1.08M | 0.622% |
| CGEM Cullinan Therapeutics, Inc. | +45.0K | +185.9% | $819.12K | 0.726% |
| MDGL Madrigal Pharmaceuticals, Inc. | +1,000 | +50.0% | $536.95K | 0.928% |
| INSM INSMED Inc | +4,253 | – | $453.46K | 0.261% |
| LBRX Lb Pharmaceuticals Inc | +13.0K | – | $420.78K | 0.242% |
| CDNA CareDx, Inc. | +13.6K | – | $388.46K | 0.224% |
| QTTB Q32 Bio Inc. | +30.4K | – | $387.45K | 0.223% |
| TVTX Travere Therapeutics, Inc. | +6,649 | +4.7% | $377.73K | 4.82% |
| SNDX Syndax Pharmaceuticals Inc | +15.2K | +3.6% | $333.26K | 5.51% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CYTK Cytokinetics Inc | -23.6K | -100.0% | $1.56M | Exited |
| TGTX Tg Therapeutics, Inc. | -23.2K | -25.7% | $1.27M | 2.12% |
| BMY Bristol Myers Squibb Co | -11.6K | -85.3% | $669.66K | 0.066% |
| ADMA Adma Biologics, Inc. | -60.2K | -100.0% | $542.40K | Exited |
| JPM Jpmorgan Chase & Co | -1,379 | -7.1% | $451.39K | 3.41% |
| LENZ LENZ Therapeutics, Inc. | -33.7K | -100.0% | $308.65K | Exited |
| DD DuPont de Nemours, Inc. | -1,256 | -100.0% | $172.53K | Exited |
| JSPR Jasper Therapeutics, Inc. | -160.8K | -100.0% | $140.88K | Exited |
| MREO Mereo BioPharma Group plc | -300.3K | -100.0% | $99.11K | Exited |
| OXY Occidental Petroleum Corp | -194 | -29.3% | $9.42K | 0.013% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| CLST Catalyst Bancorp, Inc. | +114.0K | $3.58M | 2.06% |
| SPRB Spruce Biosciences, Inc. | +20.0K | $1.08M | 0.622% |
| INSM INSMED Inc | +4,253 | $453.46K | 0.261% |
| LBRX Lb Pharmaceuticals Inc | +13.0K | $420.78K | 0.242% |
| CDNA CareDx, Inc. | +13.6K | $388.46K | 0.224% |
| QTTB Q32 Bio Inc. | +30.4K | $387.45K | 0.223% |
| ELVN Enliven Therapeutics, Inc. | +6,183 | $313.79K | 0.181% |
| BSX Boston Scientific Corp | +6,000 | $256.08K | 0.148% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| CYTK Cytokinetics Inc | -23.6K | $1.56M | 1.07% |
| ADMA Adma Biologics, Inc. | -60.2K | $542.40K | 0.372% |
| LENZ LENZ Therapeutics, Inc. | -33.7K | $308.65K | 0.212% |
| DD DuPont de Nemours, Inc. | -1,256 | $172.53K | 0.118% |
| JSPR Jasper Therapeutics, Inc. | -160.8K | $140.88K | 0.097% |
| MREO Mereo BioPharma Group plc | -300.3K | $99.11K | 0.068% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | GOOG Alphabet Inc. | Technology | 91.4K | $32.30M | 18.62% | 0 | 0.0% | Unchanged | 0% |
| 2 | APO Apollo Global Management, Inc. | Financial Services | 225.0K | $26.62M | 15.34% | 0 | 0.0% | Unchanged | 0.04% |
| 3 | SNDX Syndax Pharmaceuticals Inc | Healthcare | 437.2K | $9.56M | 5.51% | +15.2K | +3.6% | Added | 0.49% |
| 4 | XERS Xeris Biopharma Holdings, Inc. | Healthcare | 1.06M | $8.40M | 4.84% | 0 | 0.0% | Unchanged | 0.61% |
| 5 | TVTX Travere Therapeutics, Inc. | Healthcare | 147.3K | $8.37M | 4.82% | +6,649 | +4.7% | Added | 0.16% |
| 6 | PTGX Protagonist Therapeutics, Inc | Healthcare | 63.0K | $7.72M | 4.45% | 0 | 0.0% | Unchanged | 0.1% |
| 7 | BBIO BridgeBio Pharma, Inc. | Healthcare | 92.9K | $6.92M | 3.99% | +2,850 | +3.2% | Added | 0.05% |
| 8 | IOVA Iovance Biotherapeutics, Inc. | Healthcare | 1.60M | $6.66M | 3.84% | 0 | 0.0% | Unchanged | 0.35% |
| 9 | ALKS Alkermes plc. | Healthcare | 121.8K | $6.38M | 3.68% | +1,759 | +1.5% | Added | 0.07% |
| 10 | JPM Jpmorgan Chase & Co | Financial Services | 18.1K | $5.92M | 3.41% | -1,379 | -7.1% | Reduced | 0% |
| 11 | COGT Cogent Biosciences, Inc. | Healthcare | 111.1K | $4.30M | 2.48% | +7,081 | +6.8% | Added | 0.06% |
| 12 | TGTX Tg Therapeutics, Inc. | Healthcare | 66.8K | $3.67M | 2.12% | -23.2K | -25.7% | Reduced | 0.04% |
| 13 | CLST Catalyst Bancorp, Inc. | Financial Services | 114.0K | $3.58M | 2.06% | +114.0K | – | New | 2.83% |
| 14 | AGIO Agios Pharmaceuticals, Inc. | Healthcare | 95.1K | $3.53M | 2.03% | +2,000 | +2.1% | Added | 0.16% |
| 15 | VRDN Viridian Therapeutics, Inc.\DE | Healthcare | 181.0K | $3.32M | 1.92% | 0 | 0.0% | Unchanged | 0.16% |
Tip. Select a row to see that position’s full history at Knott David M Jr.
As of its Q2 2026 13F filing, Knott David M Jr’s five largest positions were Alphabet Inc. (GOOG) at 18.6%, Apollo Global Management, Inc. (APO) at 15.3%, Syndax Pharmaceuticals Inc (SNDX) at 5.5%, Xeris Biopharma Holdings, Inc. (XERS) at 4.8%, Travere Therapeutics, Inc. (TVTX) at 4.8% of the reported portfolio.
Knott David M Jr reported a 13F portfolio worth $173.52M across 71 positions for Q2 2026. That is up 19.1% from the previous quarter.
Its largest purchases by value were Catalyst Bancorp, Inc. ($3.58M), Spruce Biosciences, Inc. ($1.08M), Cullinan Therapeutics, Inc. ($819.12K). It opened 8 new positions.
Its largest sales by value were Cytokinetics Inc ($1.56M), Tg Therapeutics, Inc. ($1.27M), Bristol Myers Squibb Co ($669.66K). It exited 6 positions entirely.
From the Form 13F-HR reports Knott David M Jr files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.